ParagonRx® | Minimize Risk and Optimize Use

BECKER CONSULTING

FDA News Flash                                                             January 17, 2012

FDA REGULATORY NEWS

• Christy Foreman, Director of FDA’s Office of Device Evaluation (ODE) within the Center for Devices and Radiological Health (CDRH), announced the creation of a new Chief Medical Officer position within ODE in order to add clinical support to assist with complex review issues and establish consistent clinical policies.  Dr. Randall Brockman, Medical Officer in the Division of Cardiovascular Devices, will serve as the interim Chief Medical Officer until the position is officially created and permanently filled.  (Health News Daily)
• FDA’s CDRH is planning to launch a survey to asses obese patients’ tolerance for risk to achieve potential benefit from new obesity devices, in order to better integrate patient perspective into benefit-risk analysis during regulatory decision-making.  This is the first survey conducted by CDRH which focuses on evaluating patient risk tolerance, and may inform future CDRH methods of weighing risks and benefits of devices during regulatory review.  (The Gray Sheet)       

FDA COMPLIANCE NEWS

• FDA has announced the reissuance of an updated version of the Healthcare Professional Survey of Prescription Drug Promotion, a survey assessing the perceptions of healthcare providers as to how direct-to-consumer (DTC) advertising affects their practices and patient relationships.  The new version of the survey will include nurses and physician assistants in addition to physicians in order to further FDA’s understanding of how DTC advertising affects health outcomes in patients.  [FR Notice] (The Pink Sheet Daily)
• FDA is expanding the types of information collected by the agency’s Bioresearch Monitoring Information System to include clinical investigator financial arrangements or interests in a study sponsor, and is being updated to include data from newly created FDA offices.  The Agency is also amending the system’s “routine use” clauses to enable FDA to disclose information to other government agencies and international organizations, sponsors and institutional review boards, research subjects, and the general public.  (The Gray Sheet)

CLIENT NEWS

• AstraZeneca outlines commitment to collaborative research partnerships to bolster product pipeline (InPharm)
• Boston Scientific Epic™ stent demonstrates positive clinical outcomes in Orion trial (PRNewswire)
• Roche, GlaxoSmithKline breast cancer drugs nearly twice as effective in treatment when combined versus single-drug therapy according to study (Bloomberg)
• Ventana, Bayer enter strategic collaboration to develop companion diagnostic test for new biological cancer therapy (FierceMedicalDevices)

For additional information, please respond to dailydose@becker-consult.com.

MEETINGS

This week

• Tobacco Products Scientific Advisory Committee Meeting.  January 18-19, 2012.  Discuss issues related to the nature and impact of the use of dissolvable tobacco products on the public health, including such use among children, and discuss topics such as the composition and characteristics of dissolvable tobacco products, product use, potential health effects, and marketing.  [FR Notice]

• Advisory Committee for Reproductive Health Drugs.  January 20, 2012.  Discuss the benefits and risks of new drug application 22-139 progesterone gel 8%, Columbia Laboratories, Inc., for the proposed indication of “reduction of risk of preterm birth in women with short uterine cervical length regardless of other risk factors in the mid-trimester of pregnancy.”  Columbia Laboratories, Inc., (NASDAQ:CBRX).  [FR Notice]

Next 30 days

• Pediatric Advisory Committee.  January 30, 2011.  Discuss pediatric-focused safety reviews, as mandated by the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act for Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Cervarix (Human Papillomavirus Bivalent (Types 16 and 18) vaccine, recombinant, Focalin XR (dexmethylphenidate), Daytrana (methylphenidate), Seroquel (quetiapine), Pancreaze (pancrelipase), Zenpep (pancrelipase), Creon (pancrelipase), Xerese cream 5%/1% (acyclovir and hydrocortisone), Xolair (omalizumab), Benicar (olmesartan medoxomil), Atacand (candesartan cilexetil), Mirena (levonorgestrel— releasing intrauterine system), Plan B One Step (levonorgestrel), and Flomax (tamsulosin).  [FR Notice]
• Oncologic Drugs Advisory Committee.  February 8, 2012.  Discuss supplemental biologics license application 125320/28 for XGEVA (denosumab) injection, application submitted by Amgen, Inc.  The proposed indication for this product is for the treatment of men with castrate-resistant prostate cancer at high risk of developing bone metastases, or spread of cancer to the bones.  Amgen, Inc., (NASDAQ:AMGN).  [FR Notice]
• Oncologic Drugs Advisory Committee.  February 9, 2012.  Discuss supplemental new drug application (NDA) 21790/010 for DACOGEN (decitabine) for injection, application submitted by Eisai, Inc.  The proposed indication for this product is for the treatment of acute myelogenous leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction chemotherapy.  Discuss NDA 022481, with the proposed trade name PIXUVRI (pixantrone dimaleate) injection, application submitted by Cell Therapeutics, Inc.  The proposed indication for this product is as a single agent treatment for patients with relapsed or refractory, aggressive Non-Hodgkin’s Lymphoma who received two or more prior lines of therapy.  Cell Therapeutics, Inc., (NASDAQ:CTIC).  [FR Notice]
• Anesthetic and Analgesic Drug Products Advisory Committee.  February 9, 2012.  Discuss the available efficacy and safety data for supplemental new drug application (sNDA) 22395/S–013, QUTENZA (capsaicin 8%) Patch, by NeurogesX, Inc., for the proposed indication of management of neuropathic pain (nerve pain) related to HIV-associated peripheral neuropathy.  NeurogesX, Inc., (NASDAQ:NGSX).  [FR Notice]
• Neurological Devices Panel of the Medical Devices Advisory Committee.  February 10, 2012.  Discuss and make recommendations regarding the possible reclassification of cranial electrotherapy stimulator (CES) devices.  [FR Notice]

• Cellular, Tissue, and Gene Therapies Advisory Committee.  February 10, 2012.  Hear updates of the research programs in the Cellular and Tissue Branch, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, FDA.  [FR Notice]

Next 90 days

• Endocrinologic and Metabolic Drugs Advisory Committee.  February 22, 2012.  Discuss the safety and efficacy of new drug application (NDA) 22-580, proposed trade name QNEXA (phentermine/topiramate) Controlled-Release Capsules, manufactured by VIVUS, Inc., as an adjunct to diet and exercise for weight management in patients with a body mass index (BMI) equal to or greater than 30 kilograms (kg) per square meter or a BMI equal to or greater than 27 kg per square meter if accompanied by weight-related comorbidities.  VIVUS, Inc., (NASDAQ:VVUS).  [FR Notice]
• Cardiovascular and Renal Drugs Advisory Committee.  February 23, 2012.  Discuss the new drug application (NDA) 203202, proposed trade name NORTHERA (droxidopa capsules), submitted by Chelsea Therapeutics, Inc., for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson’s Disease, Multiple System Atrophy, and Pure Autonomic Failure), Dopamine Beta-Hydroxylase Deficiency, and Non-Diabetic Autonomic Neuropathy.  Chelsea Therapeutics, Inc., (NASDAQ:CHTP).  [FR Notice]
• Dermatologic and Ophthalmic Drugs Advisory Committee.  February 27, 2012.  Comment on the following topics related to the use of ophthalmic drug products:  Appropriate types of clinical evidence for developing anti-inflammatory drugs for the treatment of postoperative drugs and reduction of ocular pain in patients who have undergone ocular surgery; and the appropriateness of marketing a single bottle of ophthalmic product for use in both eyes for postsurgical indications as it relates to the potential risk for infection.  [FR Notice]
• FDA Rare Disease Patient Advocacy Day.  March 1, 2012.  Meeting to enhance the awareness of the rare disease community as to FDA’s roles and responsibilities in the development of products (drugs, biological products, and devices) intended for the diagnosis, prevention, and/or treatment of rare diseases or conditions.  [FR Notice] 
• Public Workshop.  March 7-8, 2012.  FDA Clinical Trial Requirements, Regulations, Compliance, and Good Clinical Practice.  Co-sponsored by the FDA Los Angeles District Office and the Society of Clinical Research Associates (SoCRA).  Aid the clinical research professional’s understanding of the mission, responsibilities, and authority of the FDA and to facilitate interaction with FDA representatives; focus on the relationships among FDA and clinical trial staff, investigators, and institutional review boards (IRB).  [FR Notice]
• Arthritis Advisory Committee Meeting.  March 12, 2012.  Discuss the anti-nerve growth factor (Anti-NGF) drug class that is currently under development and the safety issues possibly related to these drugs.  [FR Notice]
• Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting.  March 14, 2012.  Discuss the clinical pharmacology aspects of  pediatric clinical trial design and dosing to optimize pediatric drug development.  [FR Notice]
• Public Workshop.  May 3, 2012.  Clinical Development Programs for Sedation Products.  Solicit information on a variety of issues related to the clinical development and use of sedation products in adult and pediatric age groups as FDA develops guidance on clinical development programs for sedation products.  [FR Notice] 
• Public Workshop.  April 12, 2012.  Role of Naloxone in Opioid Overdose Fatality Prevention.  [FR Notice]
• POSTPONED:  Immunology Devices Panel.  TBD.  Discuss, make recommendations, and vote on a premarket approval application for the Progensa PCA3 assay, which is indicated to aid in the decision for repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies and for whom a repeat biopsy would be recommended based on current standard of care, before consideration of PCA3 assay results.  Gen-Probe, Inc., (NASDAQ:GPRO).  [FR Notice]

To be added to the daily distribution list, please reply to this message (dailydose@becker-consult.com) with your complete contact information, including your email address.

Becker Daily Dose is a trademark of Becker & Associates Consulting, Inc.  Copyright © 2011.  All rights reserved.